<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245544</url>
  </required_header>
  <id_info>
    <org_study_id>0759-004</org_study_id>
    <secondary_id>MK0759-004</secondary_id>
    <secondary_id>2005_078</secondary_id>
    <nct_id>NCT00245544</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Explore the Safety and Preliminary Efficacy of Oral MK0759 in the Treatment of Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and effect of MK0759 in relieving neuropathic
      pain as experienced by patients with postherpetic neuralgia (PHN).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity recorded by the patient each evening using an 11-point Likert scale (0=no pain to 10=pain as bad as you can imagine).</measure>
    <time_frame>Duration of Treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety; Patient Global Impression of Change assessed at the end of each treatment period.</measure>
    <time_frame>Duration of Treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Neuralgia, Postherpetic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0759</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 85; diagnosis of postherpetic neuralgia with pain having persisted at least
             6 months; dissatisfied with current regimen of pain control; able to complete study
             questionnaires, patient diary, and comply with daily study medication

        Exclusion Criteria:

          -  Women of childbearing potential; history or evidence of a condition that, in the
             opinion of the investigator, may interfere with the study interpretation (e.g.,
             diabetic neuropathy or fibromyalgia) or pose undue risk to undergo the course of
             medication required by the study (e.g., unstable heart disease, morbid obesity, kidney
             or liver disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2005</study_first_submitted>
  <study_first_submitted_qc>October 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

